89Zr-Radiolabeled Trastuzumab Imaging in Orthotopic and Metastatic Breast Tumors
Open Access
- 4 January 2012
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 5 (1) , 79-93
- https://doi.org/10.3390/ph5010079
Abstract
The human epidermal growth factor receptor 2 (HER2/neu) is overexpressed in 20–30% of breast cancers and is associated with tumor growth, angiogenesis, and development of distant metastases. Trastuzumab, an anti-HER2 monoclonal antibody, is used for the treatment of HER2 positive breast cancer and clinical efficacy of this agent is dependent on HER2 expression. Targeted PET imaging of HER2 with radiolabeled trastuzumab may be used to determine HER2 expression levels and guide therapy selection. The purpose of the current study was to evaluate a facile 89Zr-trastuzumab preparation method that can be efficiently applied for clinical grade production. Also, relative HER2 expression levels in orthotopic and metastatic breast cancer models were assessed by PET imaging using the 89Zr-trastuzumab produced by this simpler method.Keywords
This publication has 44 references indexed in Scilit:
- Molecular imaging of HER2-positive breast cancer: a step toward an individualized ‘image and treat’ strategyCurrent Opinion in Oncology, 2010
- A Pretherapy Biodistribution and Dosimetry Study of Indium-111-Radiolabeled Trastuzumab in Patients with Human Epidermal Growth Factor Receptor 2-Overexpressing Breast CancerCancer Biotherapy & Radiopharmaceuticals, 2010
- Positive Progress in ImmunoPET—Not Just a CoincidenceCancer Biotherapy & Radiopharmaceuticals, 2010
- Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast CancerClinical Pharmacology & Therapeutics, 2010
- Management of breast cancer with targeted agents: importance of heterogenicityNature Reviews Clinical Oncology, 2010
- p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imagingEuropean Journal of Nuclear Medicine and Molecular Imaging, 2009
- Standardized methods for the production of high specific-activity zirconium-89Published by Elsevier ,2009
- Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with 64Cu-DOTA-trastuzumabEuropean Journal of Nuclear Medicine and Molecular Imaging, 2009
- EGF–ERBB signalling: towards the systems levelNature Reviews Molecular Cell Biology, 2006
- Comparison of HER2 status between primary tumor and disseminated tumor cells in␣primary breast cancer patientsBreast Cancer Research and Treatment, 2006